AbbVie licenses two preclinical migraine programs from China’s Brise Pharmaceuticals in a $757M deal that dates back to 2024.
Fresenius gets exclusive options on up to 37 WuXi Biologics biosimilar candidates, potentially more than doubling its 29-molecule portfolio.
FDA sets May 1 deadline for UniQure's Huntington's gene therapy; Inovio's Voceryq approved for RRP; AbbVie wins Botox IRA ...
Karyopharm files for Chapter 11 and plans a merger with Gamida Cell parent Ayrmid, backed by $55M in DIP financing; shares fall 84%.
Regulators issued the hold for Bright Minds' BMB-101 after identifying toxicity issues in preclinical mouse models.
Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...
Aspen Neuroscience raises ~$141M and Bambusa ~$169M in Nasdaq IPOs, pushing 2026 biotech IPO haul to ~$8B across 29 deals.
Sanofi will keep launching new medicines across Europe under Trump’s MFN policy, possibly at higher prices, its CFO says.
Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...
AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in ...
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...
Bristol Myers touts 7% Q3 revenue growth and admilparant progress as it faces 2028 patent cliffs for Eliquis and Opdivo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results